X

Drug Profile

Research programme: diabetes therapy - MIGENIX

Alternative Names: MITO 2915; MITO 3384; MITO 4837

Latest Information Update: 25 May 2005

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator MIGENIX
Class Small molecules
Mechanism of Action Mitochondrial protein stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

No development reported Type 2 diabetes mellitus

Most Recent Events

25 May 2005 No development reported - Preclinical for Type-2 diabetes mellitus in USA (unspecified route)
28 Sep 2004 Micrologix Biotech is now called MIGENIX
06 Sep 2004 MitoKor has been acquired and merged into Micrologix Biotech

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com